

PA48: Summary of Internal Concentration

Study Number: C11042B-01
 Test Type: TOX with Perinatal Exposure
 Route: Whole-Body Inhalation
 Species/Strain: Rat/Harlan Sprague Dawley

Test Compound: Triphenyl Phosphate (TPHP)
 CAS Number: 115-86-6
 DTXSID: DTXSID1021952

Date: 08 May 2026
 Time: 12:53:03 PM

F0 Females/F1 Pups

	Phase	Treatment Group (ppm)						
		0	30	100	300	1000	3000	
F0 Female								
Fetal TPHP Concentration (ng/g)	GD 18	BD	BD	5.54 ± 0.515[3]	9.97 ± 2.38[3]	28.0 ± 2.11[3]	244 ± 72.5[3]	
Maternal Plasma TPHP Concentration (ng/mL)	GD 18	BD	BD	4.41 ± 0.984[3]	6.80 ± 1.46[3]	27.2 ± 2.53[3]	247 ± 70.9[3]	
Maternal Plasma TPHP Concentration (ng/mL)	LD 4	BD	BD	3.35 ± 0.0458[3]	16.2 ± 3.25[3]	33.5 ± 1.79[3]	195 ± 1.45[3]	
F1 Male								
Pup Plasma TPHP Concentration (ng/mL)	PND 4	BD	BD	BD	1.93 ± 0.492[14][4]	10.7 ± 4.01[14][4]	75.9 ± 37.0[15][5]	
F1 Female								
Pup Plasma TPHP Concentration (ng/mL)	PND 4	BD	BD	BD	BD	7.59 ± 1.67[14][6]	33.3 ± 8.98[12][4]	

PA48: Summary of Internal Concentration

Study Number: C11042B-01
 Test Type: TOX with Perinatal Exposure
 Route: Whole-Body Inhalation
 Species/Strain: Rat/Harlan Sprague Dawley

Test Compound: Triphenyl Phosphate (TPHP)
 CAS Number: 115-86-6
 DTXSID: DTXSID1021952

Date: 08 May 2026
 Time: 12:53:03 PM

F1 Adult Males

	Phase	Treatment Group (ppm)					
		0	30	100	300	1000	3000
Urine Creatinine Concentration (mg/dL)	PND 118	199 ± 28.3[5]	209 ± 33.5[5]	183 ± 26.6[5]	186 ± 21.6[5]	225 ± 41.7[5]	236 ± 30.2[5]
Urine TPHP Concentration (ng/mL)	PND 118	BD	64.7 ± 10.9[5]	143 ± 15.9[4]	869 ± 154[5]	2020 ± 281[5]	8490 ± 2720[5]
Urine TPHP Concentration per Creatinine (ng/mg Creatinine)	PND 118	BD	34.3 ± 8.44[5]	97.0 ± 26.7[4]	474 ± 70.6[5]	1000 ± 204[5]	3320 ± 603[5]
Urine DPHP Concentration (ng/mL)	PND 118	7.47 ± 1.34[5]**	3920 ± 302[5]**	8840 ± 1810[5]**	28000 ± 2220[5]**	89800 ± 12100[5]**	313000 ± 33100[5]**
Urine DPHP Concentration per Creatinine (ng/mg Creatinine)	PND 118	3.69 ± 0.224[5]**	1990 ± 210[5]**	4600 ± 417[5]**	15400 ± 845[5]**	41700 ± 3690[5]**	141000 ± 23600[5]**
Plasma TPHP Concentration (ng/mL)	PND 128	BD	BD	2.40 ± 1.50[2]	3.75 ± 1.13[5]	12.3 ± 1.27[5]	54.3 ± 18.0[5]
Brain TPHP Concentration (ng/g)	PND 128	2.95 ± 0.307[5]**	1.56 ± 0.415[5]	6.34 ± 2.30[5]	7.71 ± 0.909[5]*	16.9 ± 2.35[5]**	70.1 ± 24.7[5]**

PA48: Summary of Internal Concentration

Study Number: C11042B-01
 Test Type: TOX with Perinatal Exposure
 Route: Whole-Body Inhalation
 Species/Strain: Rat/Harlan Sprague Dawley

Test Compound: Triphenyl Phosphate (TPHP)
 CAS Number: 115-86-6
 DTXSID: DTXSID1021952

Date: 08 May 2026
 Time: 12:53:03 PM

F1 Adult Females

	Phase	Treatment Group (ppm)					
		0	30	100	300	1000	3000
Urine Creatinine Concentration (mg/dL)	PND 118	93.0 ± 15.6[5]	83.3 ± 19.7[5]	137 ± 28.0[5]	125 ± 22.9[5]	103 ± 17.2[5]	123 ± 16.1[5]
Urine TPHP Concentration (ng/mL)	PND 118	BD	BD	BD	BD	BD	9.03 ± 2.53[5]
Urine TPHP Concentration per Creatinine (ng/mg Creatinine)	PND 118	BD	BD	BD	BD	BD	7.31 ± 1.95[5]
Urine DPHP Concentration (ng/mL)	PND 118	16.0 ± 5.93[5]**	496 ± 196[5]**	1450 ± 365[5]**	5210 ± 1500[5]**	11700 ± 1900[5]**	42000 ± 7510[5]**
Urine DPHP Concentration per Creatinine (ng/mg Creatinine)	PND 118	16.5 ± 5.76[5]**	522 ± 166[5]**	1070 ± 122[5]**	4040 ± 557[5]**	11800 ± 1140[5]**	33900 ± 3440[5]**
Plasma TPHP Concentration (ng/mL)	PND 128	BD	BD	BD	3.44 ± 1.18[5]	21.8 ± 11.0[5]	59.4 ± 11.8[5]
Brain TPHP Concentration (ng/g)	PND 128	2.78 ± 0.170[5]**	1.16 ± 0.260[4]	2.81 ± 0.611[5]	8.63 ± 0.685[5]*	35.5 ± 15.2[5]**	164 ± 28.5[5]**

PA48: Summary of Internal Concentration

Study Number: C11042B-01 Test Compound: Triphenyl Phosphate (TPHP) Date: 08 May 2026
Test Type: TOX with Perinatal Exposure CAS Number: 115-86-6 Time: 12:53:03 PM
Route: Whole-Body Inhalation DTXSID: DTXSID1021952
Species/Strain: Rat/Harlan Sprague Dawley

LEGEND

For the PND 4 Pup Plasma TPHP Concentrations, the data are displayed as mean \pm SEM of litter means [Number of pups][Number of litters]. For all other results, data are displayed as mean \pm SEM [Number of animals].

If over 20% of the animals in a group were above the limit of detection, then 1/2 the limit of detection value was substituted for values that were below the limit of detection.

The limit of detection was 1.8 ng/g for TPHP concentrations and 0.5 ng/g for DPHP concentrations.

When the control group did not have over 20% of its values above the limit of detection, no mean or standard error were calculated and no statistical analysis was done for the endpoint.

"Per Creatinine" urine endpoints were calculated as $100 * (\text{Urine TPHP/DPHP Concentration (ng/mL)} / \text{Creatinine Concentration (mg/dL)})$

If over 20% of the Urine TPHP or DPHP Concentration values were above the limit of detection, the corresponding creatinine-adjusted calculations were performed using 1/2 the limit of detection value for the particular endpoint.

Statistical analysis was performed by Jonckheere (trend) and Shirley or Dunn (pairwise) tests.

Statistical significance for the control group indicates a significant trend test.

Statistical significance for a treatment group indicates a significant pairwise test compared to the vehicle control group.

* Statistically significant at $p \leq 0.05$

** Statistically significant at $p \leq 0.01$

BD - Group did not have over 20% of its values above the limit of detection.

GD = Gestation Day; LD = Lactation Day; PND = Postnatal Day

SEM = Standard Error of the Mean

The following values were excluded as outliers: one GD 18 fetal TPHP concentration value from the 30 ppm group, one LD 4 maternal plasma TPHP concentration value from the 30 ppm group, one female PND 4 pup plasma concentration from the 100 ppm group, one F1 female brain TPHP concentration from the 30 ppm group, one F1 female urine concentration from the 30 ppm group, one male PND 4 pup plasma TPHP concentration from the 100 ppm group, and one F1 male urine TPHP concentration from the 100 ppm group.

F1 urine measurements from the PND 118 cohort were obtained between PND 117 and 119; F1 brain and plasma measurements from the PND 128 cohort were taken between PND 125 and 129.

**** END OF REPORT ****